Cancer treatment, vaccines and recurrence prevention

Source date: 2026-11-09. Evidence: Sponsor-only uncontrolled Phase 2 topline. Appraisal: November 10 scheduled run, completed November 11 UTC; source dates are not retrieval dates.

Faeth’s November 9 original filing reports NCT06463028/GOG-3111, open-label single-arm Phase 2 serabelisib plus sapanisertib (PIKTOR) with paclitaxel, in advanced endometrioid endometrial cancer with a PI3K/AKT/mTOR-pathway mutation after at least one prior treatment line. 42 were treated; efficacy cutoff was October 30.

Confirmed responses occurred in 12/36 efficacy-evaluable patients (33%), with six excluded before the first post-baseline scan, including three with early progression. The selected PIK3CA subgroup had 7/16 responses. Preliminary median PFS in all 42 treated was 7.4 months (95% CI 5.3 to not reached). These are not comparative survival benefits; excluding early progressors matters for the headline response rate.

Safety cutoff October 23: 64% had grade ≥3 treatment-related adverse events; grade ≥3 neutropenia occurred in 26%. Two patients (5%) discontinued for treatment-related events; no treatment-related deaths were reported. The sponsor plans Phase 3 advancement, without a verified start date. PIKTOR remains investigational; neither response nor filing this disclosure establishes approval.

Next milestones: Phase 3 planning is sponsor intent; protocol, initiation and confirmatory benefit dates unknown.

Sources: investors.faeththerapeutics.com · source document; ClinicalTrials.gov · NCT06463028.

Source date: 2026-11-09. Evidence: New trial-registry protocols; no outcomes. Appraisal: November 10 scheduled run, completed November 11 UTC; source dates are not retrieval dates.

NCT07924111, first posted November 9, plans 585 patients with residual esophageal squamous-cell cancer after complete resection. Three masked arms compare SG001/enlonstobart plus the EGFR ADC SYS6010, SG001 alone with matching placebo, and matching placebos. Disease-free survival is primary; overall survival and harms are separate endpoints. Status is not yet recruiting; estimated start December 30, 2026, primary completion December 30, 2029, final completion December 30, 2030.

Separate NCT07925021, also posted November 9, lists recruiting and plans 424 systemic-treatment-naive recurrent/metastatic nasopharyngeal-cancer patients. SYS6010/enlonstobart is compared with tislelizumab plus chemotherapy; blinded independent-review PFS is primary. The text describes randomization, but the structured allocation field says not applicable; preserve that inconsistency. Its November 6 start is estimated, not proof of first dosing, with primary completion October 2029 and final December 2030 estimates.

No results, comparative harms or new U.S. approval are established. Adjuvant recurrence prevention in people already treated for cancer is distinct from primary prevention in healthy people.

Next milestones: Esophageal study estimated December 30, 2026 start; primary-completion forecasts late 2029, not publication dates.

Sources: ClinicalTrials.gov · NCT07924111; ClinicalTrials.gov · NCT07925021.

Coverage and remaining gaps: Focused, incomplete review. All pages of the specified U.S. registry discovery and saved identifiers were retrieved; retrieval is not full appraisal. Global registers, every paper/supplement and the complete regulatory/harms census remain incomplete. Full-success and baseline flags stay unchanged. Run record.

Source date: 2026-11-05. Recorded in this review: November 6, 2026.

FDA approved subcutaneous amivantamab/hyaluronidase-lpuj for adults with recurrent/metastatic HNSCC progressing after platinum chemotherapy and anti-PD-(L)1 treatment; HPV-associated oropharyngeal cancer is excluded. OrigAMI-4 (NCT06385080), an open-label Phase 1b/2 study, supplied 102 efficacy patients: independently reviewed response rate 42% (95% CI 32–52%); 56% of responders lasted at least six months.

Limitations: Accelerated approval rests on tumor response/duration, not proven comparative survival. Historical response comparisons are not a randomized control. Continued approval depends on confirmatory clinical benefit; first-line OrigAMI-5 is a different treatment setting.

Safety: In the 102-patient cohort, rash 79%, fatigue 39%, nail toxicity 35%, stomatitis 32%, edema 28%; serious adverse reactions 39%, fatal adverse events 6%. Warnings include hypersensitivity/administration reactions, ILD/pneumonitis, ocular/skin toxicity and embryo-fetal harm. Do not combine these figures with lung-cancer combination cohorts.

U.S. status: New FDA-approved indication for this subcutaneous product; actual local access/coverage not independently assessed.

Next milestone: Confirmatory first-line Phase 3 OrigAMI-5 (NCT07276399), recruiting; registry estimates primary completion June 18, 2029 and final July 18, 2029. These are completion estimates, not a promised result-release date.

Sources: FDA indication and efficacy review; Sponsor announcement and indication-specific safety; Confirmatory OrigAMI-5 registry.

Source date: 2026-10-28. Recorded in this review: November 6, 2026.

Recovered original October 28 SELLAS release: Phase 3 REGAL (NCT04229979), galinpepimut-S maintenance after second AML remission, reached the prespecified 80th death. That triggers database lock, unblinding and analysis of overall survival. The company forecasts preliminary primary-endpoint results in Q4 2026, without a day. This closes the earlier monitoring gap; the notice is not November news or an efficacy readout.

Limitations: Aggregate event accrual cannot reveal arm-specific survival, treatment benefit or cure. The saved October 2 Reddit “any day” calculation is not validated by eventual occurrence, and its stock-price claims remain unsupported.

Safety: No new comparative harms tables in the announcement.

U.S. status: Investigational; no FDA approval established.

Next milestone: Preliminary REGAL overall-survival topline Q4 2026 after final analysis (sponsor forecast).

Sources: Original October 28 final-analysis-trigger release.

Source date: 2026-11-04. Recorded in this review: November 6, 2026.

SELLAS reports a completed dose-ranging Phase 2 SLS009 (tambiciclib)+azacitidine+venetoclax cohort: 62 heavily pretreated relapsed/refractory AML patients, 59 efficacy-evaluable. Across doses, response was 34% (12 CR/CRi and 8 morphologic leukemia-free states). At 30 mg twice weekly, sponsor reports 54% response / 5.8-month median survival in monocytic AML and57%/8.8 months in TP53-mutated AML. Presentation: ASH abstract5155, December 14, 6–8 p.m. Central.

Limitations: No randomized comparator; historical ~2.5-month survival is not a treatment-effect estimate. Subgroup denominators, CIs and full follow-up tables absent from the release. Do not conflate this relapsed study with separate newly diagnosed80-patient Phase 2 enrollment or GPS/REGAL.

Safety: Sponsor describes predominantly grade1/2 nausea/diarrhea and limited additional toxicity/treatment-related deaths, but exact rates/counts not supplied; do not turn ambiguous wording into zero deaths.

U.S. status: Investigational CDK9-inhibitor combination; no new approval.

Next milestone: ASH December 14,2026 poster scheduled; separate frontline early topline Q4 2026 sponsor forecast.

Sources: Original sponsor November 4 ASH disclosure; ClinicalTrials.gov NCT04588922.

Coverage and remaining gaps: focused_incomplete; No complete worldwide oncology or ASH abstract census; SLS009 subgroup denominators, CIs and full original tables remain missing. ALPHA3 November 5 timing lead passed to root for deduplication.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal-source coverage: Original REGAL post and sponsor release reconciled: final-analysis trigger occurrence is confirmed; the exact timing calculation, efficacy and stock-price claims are not.

Full coverage record.

Source date: 2026-10-26. Recorded in this review: November 3, 2026.

Corcept's original October 26 announcement, repeated in November 3 earnings, reports BELLA Part A/NCT06906341 in 95 patients with platinum-resistant ovarian cancer: investigator-assessed median progression-free survival 7.2 months, objective response 59%, and 88% alive at six months. Median overall survival was not reached at the primary analysis. The regimen combines relacorilant, nab-paclitaxel and bevacizumab in an open-label, nonrandomized cohort.

The bevacizumab-naive subgroup had apparently stronger outcomes but also fewer prior treatment lines. This cannot establish that adding relacorilant improves survival over a concurrent comparator, or that prior bevacizumab determines treatment benefit. No confidence intervals, full follow-up distribution or exact adverse-event/discontinuation tables were supplied. Events affecting at least 25% included neutropenia, anemia, nausea, asthenia, nail disorder, peripheral neuropathy, fatigue and leukopenia; no new signal was reported.

The existing FDA-approved Lifyorli plus nab-paclitaxel indication is narrower: adults with platinum-resistant epithelial ovarian/fallopian-tube/primary-peritoneal cancer after one to three prior regimens, including bevacizumab. It does not itself authorize this three-drug regimen or a bevacizumab-naive population. Known label risks include neutropenia/severe infections and adrenal insufficiency. The sponsor plans full Part A results at a medical conference in 2027; the precise meeting/date is unannounced.

U.S. status: The two-drug Lifyorli+nab-paclitaxel regimen has an existing indication-specific FDA approval; BELLA triple-regimen evidence remains investigational.

Next milestones: Full BELLA Part A conference presentation: 2027 (Sponsor forecast; exact meeting/date unknown).

Sources: ir.corcept.com · news release; ClinicalTrials.gov · NCT06906341; FDA · prescribing information; ir.corcept.com · news release.

Source date: 2026-11-03. Recorded in this review: November 3, 2026.

Corcept reports that BELLA Part C has completed enrollment of 92 patients with endometrial cancer after one or two prior lines, receiving relacorilant plus nab-paclitaxel. Results are forecast by the end of 2027, without an exact day. This is a separate disease/cohort from the ovarian Part A topline and the existing ovarian approval.

Part B, targeting 90 platinum-sensitive ovarian-cancer patients who progressed on a PARP inhibitor, is nearing enrollment completion; its results are also forecast by end-2027. No new Part B/C response, PFS, OS or adverse-event results were disclosed. A sponsor's completion announcement does not establish favorable efficacy or a new indication.

U.S. status: No new endometrial or platinum-sensitive ovarian FDA indication established.

Next milestones: BELLA Part B/C results: 2027 (Sponsor forecast: by end of year).

Sources: ir.corcept.com · news release; ClinicalTrials.gov · NCT06906341.

Related findings, recorded once: SER-155 full paper reports an early post-transplant infection signal (Nature · article).

Coverage and remaining gaps: focused_incomplete. Complete BELLA tables/intervals and numerical safety remain missing. Not all 738 discovery records, new ADC combinations and updated result tables were appraised. Saved vaccine suspensions remain operational; updated status dates are not new efficacy events.; Complete worldwide registry, publication, safety and informal-source appraisal remains unfinished. Retain full successful-check timestamp.

Informal-source coverage: Original REGAL event80 investment-forum inference and current sponsor program page revisited; no source-verified unblinding/topline completion or new supported date established. Dynamic news index remains poorly exposed.

Full coverage record.

Source date: 2026-10-29. Recorded in this review: October 30, 2026. Event/approval date: 2026-10-25.

The October 29 final report follows an October 25 ESMO presentation. Combi-TED (NCT04884282) randomized 106 HLA-A2-positive metastatic NSCLC patients after chemo-immunotherapy: Tedopi/docetaxel (36), Tedopi/nivolumab (35), or docetaxel (35). Median OS was 11.9, 11.3 and 6.4 months, respectively (90% CIs 8.9–15.3, 6.1–13.3 and 5.2–9.0).

The primary one-year survival tests compare each arm with a 20% historical benchmark, not directly with the randomized control. Exploratory Bayesian probabilities of improvement versus control were 94.6%/92.8%, below the prespecified 95% go threshold. This is a promising small-study signal, not demonstrated Phase 3 superiority. Docetaxel dosing also differed between combination and control. Drug-related serious adverse events were 17%, 24% and 17%. A November 4 webcast is scheduled; no new approval is announced.

U.S. status: Tedopi remains investigational in the checked sources; no U.S. approval established.

Next milestones: Combi-TED expert webcast, 11 a.m. Eastern: 2026-11-04 (scheduled).

Sources: ml-eu.globenewswire.com · source page; ClinicalTrials.gov · NCT04884282.

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

Exelixis now forecasts Q1 2027 topline results for STELLAR-304 (NCT05678673), zanzalintinib/nivolumab versus sunitinib in previously untreated advanced non-clear-cell renal cancer. PFS and response are primary; OS is secondary. The July registry records 317 actual participants and remains active, not recruiting.

The sponsor also reports that STELLAR-202 (NCT07845786), testing zanzalintinib/pembrolizumab maintenance for squamous NSCLC, initiated in October 2026 and is enrolling. The stale September registry still says not yet recruiting with a December 15 estimate; the sponsor update and registry snapshot disagree, and neither supplies an exact first-dose day.

For previously treated metastatic colorectal cancer, the sponsor reiterates an FDA review target of March 3, 2027, extended in September. This is not a new October approval or efficacy result. The earlier ITT OS benefit and nonsignificant final non-liver-metastasis OS endpoint remain separate.

U.S. status: Investigational; the colorectal application is under review, not approved.

Next milestones: STELLAR-304 topline: 2027-Q1 (sponsor-forecast); Zanzalintinib colorectal FDA target action date: 2027-03-03 (sponsor-forecast).

Sources: ir.exelixis.com · news release; ClinicalTrials.gov · NCT05678673; ClinicalTrials.gov · NCT07845786.

Source date: 2026-10-30. Recorded in this review: October 30, 2026.

Three newly appraised vaccine records are suspended. NCT05642195, an adjuvant lung-cancer lysate vaccine/N-803 Phase 1/2 study, says eligibility/design revisions are being made before first enrollment (October 30 posting). PRiME II (NCT06639607), PEP-CMV/nivolumab in children/young adults with brain tumors, cites drugs/equipment unavailable (October 30). The GCC-vaccine study NCT04111172 cites FDA protocol review and funding release (October 28).

These are record posting dates, not verified dates when suspension began. The stated reasons do not establish toxicity, efficacy failure or an FDA-imposed clinical hold. None provides a verified restart date or new efficacy result. Disease-free/overall survival must remain separate from immune-response and feasibility endpoints; none tests primary prevention in healthy people.

U.S. status: These investigational uses are not approved; registry suspension is not automatically an FDA clinical hold.

Next milestones: Vaccine protocol revisions, supply/funding resolution and restart: date unknown (unknown).

Sources: ClinicalTrials.gov · NCT05642195; ClinicalTrials.gov · NCT06639607; ClinicalTrials.gov · NCT04111172.

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

CabOSTar (NCT06341712), maintenance cabozantinib plus supportive care versus supportive care in children/young adults with unresectable residual osteosarcoma, first posts results October 29. Only ten were randomized, five per group; the trial ended February 27 because of recruitment challenges.

Planned efficacy analyses were not performed. The zero analysis denominators are missing/not-analyzed evidence, not zero responses or proof of no benefit. Safety included five active-treatment and three control participants: serious adverse events occurred in 2/5 versus 0/3, and deaths in 1/5 versus 0/3. These tiny, incomplete groups do not establish comparative mortality or drug causality. The new event is delayed results disclosure, not an October safety termination. Cabozantinib's approved indications do not establish benefit in this osteosarcoma maintenance setting.

U.S. status: Investigational osteosarcoma use; other cabozantinib approvals do not establish this indication.

Next milestones: Adequately powered osteosarcoma maintenance evidence: date unknown (unknown).

Sources: ClinicalTrials.gov · NCT06341712.

Coverage and remaining gaps: focused_incomplete. INTerpath journal full paper and complete safety/OS supplements remain unverified; presentation and October22 efficacy were already saved.; Combi-TED full conference tables and between-arm confirmatory statistics remain unavailable; sponsor final report used.; Vaccine actual suspension dates and restart dates are unknown; no regulator clinical-hold inference. Full worldwide kinase/ADC/cellular/radiopharmaceutical discovery remains incomplete.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged.

Informal-source coverage: REGAL imminent-event80 community speculation remains unconfirmed; the sponsor news index is dynamically incomplete. New operational-pause records do not corroborate an efficacy or toxicity rumor. No distinct new oncology rumor selected.

Full coverage record.

Source date: 2026-10-26. Recorded in this review: October 27, 2026.

On October 26, FDA approved talazoparib (Talzenna) plus enzalutamide for adults with HRR-gene-mutated metastatic androgen-pathway-modulation-naive or sensitive prostate cancer, selected with an FDA-authorized test. This is a specific molecular/clinical population, rather than an all-prostate-cancer indication.

TALAPRO-3 (NCT04821622) randomized 599 patients to the combination or placebo plus enzalutamide, with continued androgen deprivation. Investigator-assessed radiographic progression-free survival favored talazoparib: HR 0.48 (95% CI 0.36–0.65); median not reached versus 45.8 months (37.7–not reached). Overall survival remains immature. FDA lists warnings including myelodysplastic syndrome/acute myeloid leukemia, myelosuppression, and embryo-fetal toxicity. The October label adds safety details: treated populations 299/295; in the talazoparib arm serious adverse reactions occurred in 42%, fatal adverse reactions in 3%, and permanent discontinuation in 19%. Grade 3 decreased hemoglobin occurred in 49% versus 3.4%. These are not overall grade 3+ event rates.

U.S. status: FDA approved this specific use October 26, 2026; formulation, molecular selection, and treatment setting matter.

Next milestones: Mature TALAPRO-3 overall-survival analysis: date unknown (Not announced).

Sources: FDA · regulatory information; ClinicalTrials.gov · NCT04821622; labeling.pfizer.com · source page.

Source date: 2026-10-22. Recorded in this review: October 27, 2026. Event/approval date: 2026-10-16.

FDA's decision occurred October 16 and appears as an October 22 entry in its oncology notifications. It grants traditional approval to IV pembrolizumab or subcutaneous pembrolizumab/berahyaluronidase for adults and children with previously treated, unresectable/metastatic TMB-high tumors ≥13 mutations/Mb, without satisfactory alternatives. IV and subcutaneous eligibility differ: IV includes adult/pediatric patients; Qlex pediatric use is age ≥12 and weight >40 kg.

The prior accelerated threshold was ≥10; confirmatory efficacy was not demonstrated for the 10–<13 group, so this boundary is a material limitation rather than a routine approval conversion. KEYNOTE-158 (NCT02628067) included 220 treated patients at ≥13 across prospective and prespecified retrospective cohorts: objective response was 36% (95% CI 30–43); Among 79 responders, the Kaplan–Meier proportion with response duration ≥12 months was 58%. The latter percentage applies to responders, not all treated patients. These are tumor-response data without a randomized survival comparison. Immune-mediated toxicity and other established pembrolizumab warnings remain.

U.S. status: Traditional U.S. approval October16 applies to TMB≥13 in the specified previously treated setting. IV includes adult/pediatric use; Qlex pediatric eligibility is≥12years and>40kg.

Sources: FDA · regulatory information; FDA · regulatory information; merck.com · PDF document; merck.com · PDF document.

Source date: 2026-10-24. Recorded in this review: October 27, 2026.

Moderna's October 24 recap states that the Phase 3 INTerpath-001 results were presented during an ESMO Presidential Symposium. This closes the previously upcoming presentation milestone. The recap repeats the efficacy and safety findings already recorded from the October 22 sponsor release; it should not generate a second efficacy alert or overwrite that original event date.

The adjuvant melanoma setting is prevention of recurrence after cancer treatment, not primary prevention in healthy people. Overall-survival maturity and detailed arm-level harms remain important. An independently accessible full journal paper and complete supplementary tables were not verified in this check; a scheduled talk or a sponsor recap must not be treated as those tables.

U.S. status: No new FDA approval verified from this presentation.

Next milestones: INTerpath-001 mature overall survival and complete tables: date unknown (Not verified / date not announced).

Sources: modernatx.com · source page.

Source date: 2026-10-21. Recorded in this review: October 27, 2026.

Kite/Gilead's iMMagine-4 (NCT07887672) plans 600 patients with newly diagnosed myeloma who are ineligible for transplant. Following common daratumumab/VRd induction, it compares an anitocabtagene autoleucel CAR-T consolidation strategy with continued daratumumab/Rd; the experimental strategy includes specified conditional maintenance. This is not a simple comparison of CAR-T with no treatment.

Co-primary outcomes are MRD-negative complete/stringent-complete response at 12 months and progression-free survival; overall survival, infections, and other harms need separate evaluation. The record is not yet recruiting, with estimated start January 2027 and long-term primary completion February 2042. Those estimates are not a promised first-readout schedule. No first-line efficacy or safety result is posted.

U.S. status: The registered first-line strategy is investigational; no approval follows from registration.

Next milestones: iMMagine-4 estimated start: 2027-01 (Registry estimate); iMMagine-4 first public readout: date unknown (Not announced).

Sources: ClinicalTrials.gov · NCT07887672.

Source date: 2026-10-22. Recorded in this review: October 27, 2026.

The Alliance study NCT07887984 plans 920 newly diagnosed, standard-risk myeloma patients. After common daratumumab/VRd induction, Phase 2 compares autologous stem-cell transplant with teclistamab, talquetamab, or their combination as consolidation; Phase 3 compares the selected bispecific strategy with transplant. Maintenance is part of the protocol.

Phase 2 emphasizes post-consolidation MRD-negative response; Phase 3 emphasizes progression-free survival. Overall survival and serious infections are separate outcomes, so MRD response would not by itself establish an improvement in survival or the replacement of transplantation. The record is not yet recruiting: estimated start December 23, 2026, primary completion August 1, 2033, and final completion August 1, 2053, reflecting prolonged followup rather than a promised first-readout date. No results are posted.

U.S. status: This consolidation strategy remains investigational; existing drug indications do not establish this use.

Next milestones: Bispecific-versus-transplant study estimated start: 2026-12-23 (Registry estimate); First comparative clinical readout: date unknown (Not announced).

Sources: ClinicalTrials.gov · NCT07887984.

Source date: 2026-10-22. Recorded in this review: October 27, 2026.

STARVACC (NCT07888647) plans 216 people with newly diagnosed IDH1 R132H-mutant WHO grade 3/4 astrocytoma after radiotherapy. The blinded trial compares IDH1-vac with an immune-stimulator control; both groups receive imiquimod and temozolomide. Up to 12 vaccinations are planned over three years.

The primary outcome is overall survival, with progression-free survival and patient-reported outcomes assessed separately. Earlier immune-response signals do not establish longer survival. This treats an existing cancer and is not primary prevention. The record is not yet recruiting, with estimated start February 1, 2027, primary completion February 1, 2034, and final completion February 1, 2035. No efficacy or trial safety results are posted.

U.S. status: Investigational therapeutic-vaccine strategy; no U.S. approval follows from registration.

Next milestones: STARVACC estimated start: 2027-02-01 (Registry estimate); STARVACC estimated primary completion: 2034-02-01 (Registry estimate).

Sources: ClinicalTrials.gov · NCT07888647.

Coverage and remaining gaps: focused_incomplete. Independent INTerpath journal full paper, complete supplements, and arm-level adverse-event tables not verified; do not promote secondary reported OS estimates.; Not all historical overlap-window oncology approvals were appraised (for example October 2 pirtobrutinib first-line CLL); this is an explicit regulatory coverage gap, not no news.; Some newly updated saved trials (ATOMIC, BAY2927088, DESTINY-Lung, SENTRY-CD19) and discovery records were refreshed without establishing a new material event. AZA-AEGEAN suspension remains previously reported; do not duplicate unchanged hold.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal-source coverage: status: focused_incomplete; originalSources: url: https://www.reddit.com/r/sellaslifesciences/comments/1xfmsqz/sls_weekly_in_depth_discussion_thread_week_43_2026/; date: 2026-10-26; type: original community discussion; comments not fully accessible; result: Previously saved REGAL event-80 timing remains unconfirmed. Trademark/commercial-name speculation does not confirm efficacy, trial completion, or approval. No new rumor selected; complete comment and talk review remains a gap.

Full coverage record.

U.S. status: On October 19 FDA granted accelerated approval of intravenous dostarlimab-gxly (Jemperli) alone for adults with stage II/III MSI-H or dMMR locally advanced rectal cancer, identified by an FDA-authorized solid-tumor test. This is distinct from adjuvant atezolizumab after colon-cancer surgery.

Evidence: AZUR-1/NCT05723562 treated 154 previously untreated patients. Sustained clinical complete response for twelve months was 54/116 (47%; 95% CI 37–56%) by independent central review, and 98/144 (68%; 60–76%) by investigators. Denominators, response definitions and assessments differ. The approved label Table 13 supplies the 37% lower confidence bound; FDA’s web notice instead prints 27%, an apparent transcription discrepancy that is not silently adopted. FDA reports 110/154 (71%) avoided additional treatment without progression at the cutoff; this broader status is not the primary sustained-response endpoint.

Safety/limits: Serious adverse reactions occurred in 20%, with 3% permanently discontinuing; immune-mediated injury can be severe or fatal. The single-arm evidence does not establish comparative overall survival or guaranteed cure. The label says long-term relapse risk is unknown. Close endoscopic/imaging surveillance and possible salvage treatment remain part of management.

Next: Full AZUR-1 interim data are scheduled for ESMO in October; confirmatory clinical benefit and longer relapse follow-up remain necessary.

Sources: FDA · regulatory information; gskpro.com · PDF document; gsk.com · news release.

U.S. status: FDA expanded nogapendekin alfa inbakicept-pmln (Anktiva) with BCG on October 14 to adults with BCG-unresponsive high-grade papillary-only non-muscle-invasive bladder cancer. Administration is intravesical, not a systemic treatment for all bladder cancers.

Evidence/limits: FDA’s supporting efficacy description comes from QUILT-3.032/NCT03022825 Cohort A, 77 patients with carcinoma in situ with or without papillary tumors. Complete response was 62% (95% CI 51–73%); among responders, 58% had response lasting at least twelve months and 40% at least twenty-four months. FDA says it extrapolated this demonstration to papillary-only disease because of overlapping clinical and biological characteristics. These CIS-cohort numbers are not new, directly measured papillary-only efficacy estimates or randomized survival evidence.

Safety: Common reactions/laboratory abnormalities include urinary symptoms, urinary infection, creatinine/potassium increases, chills and fever. The label warns that delaying cystectomy can permit metastatic disease and death.

Next milestone: Condition-specific real-world and confirmatory follow-up; no reliable new release date stated. Approval does not guarantee coverage or availability at every site.

Sources: FDA · regulatory information; FDA · announcement.

U.S. status: FDA approved oral tucatinib (Tukysa) with trastuzumab and pertuzumab on October 7, for maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction. This is a recovered October action, not a new October 20 approval.

Study/result: HER2CLIMB-05/NCT05132582 randomized 654 patients without progression after 4–8 cycles of trastuzumab, pertuzumab and a taxane. Median investigator-assessed progression-free survival was 24.9 months (95% CI 21.3–not reached) with tucatinib versus 16.3 (12.6–18.7) with placebo, each alongside trastuzumab/pertuzumab: HR 0.64 (0.51–0.80), p<0.0001. Overall survival was immature; PFS is not a demonstrated mortality benefit.

Safety: The October label adds a boxed warning for severe and fatal hepatotoxicity, particularly after rechallenge, with liver testing and interruption/reduction/discontinuation requirements. Diarrhea and embryo-fetal toxicity are also important. This is not treatment advice for every HER2-positive patient.

Next: The approval letter lists an overall-survival interim report in December 2030, trial completion April 2033, and final report October 2033 as postmarketing commitments, not guaranteed public presentation dates.

Sources: FDA · regulatory information; FDA · prescribing information; FDA · approval letter.

What changed: BioNTech’s October 13 announcement says AHEAD-MERIT/NCT04534205 did not meet its progression-free-survival dual primary endpoint for BNT113 (tenumomeran/raplemomeran) plus pembrolizumab versus pembrolizumab alone. The population is first-line unresectable recurrent/metastatic HPV16-positive head-and-neck squamous-cell carcinoma with PD-L1 CPS ≥1.

Evidence/limits: The randomized Phase 3 component is open-label. The release supplies no hazard ratio, confidence interval, medians, exact p value, arm denominators or detailed harms table. The independent monitoring committee recommended continuing the other dual primary endpoint, overall survival; sponsor says its prespecified design allows that test to establish a positive outcome despite the PFS miss. This is not a post hoc surrogate success, but neither is a survival benefit established.

U.S. status: Investigational. Fast Track designation is not marketing approval. This therapeutic HPV-antigen immunotherapy in existing cancer is distinct from primary-prevention HPV vaccination and personalized postoperative recurrence vaccines.

Next: Overall-survival analysis and detailed efficacy/safety disclosure; no dependable readout date in this release.

Sources: biontech.com · news release.

What changed: The October 20 update of NCT06694454/AZA-AEGEAN lists suspended, with the stated reason: “Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.” The exact date the hold began is not given; October 20 is the public registry update, not an invented onset date.

Program/evidence: The NCI Phase 1/2 study plans inhaled azacytidine with platinum-based chemotherapy and durvalumab before surgery for operable stage IB–IIIA non-small-cell lung cancer. Dose-limiting toxicity/recommended dose and pathologic complete response are principal endpoints. This is a recruitment/operational update, without posted efficacy or safety results. The record does not explain the antibody modification or establish a toxicity-triggered FDA clinical hold.

U.S. status / next: The inhaled investigational combination is not established care by this registration. An October 25 estimated start persists in the record but must not be taken as imminent verified dosing while suspended. Await a protocol amendment and explicit recruitment-resumption confirmation; no reliable restart date.

Sources: ClinicalTrials.gov · NCT06694454.

Development stage: BEX101/NCT07882641 was first posted October 20 as a single-arm, open-label Phase 1/2 study in 20 planned adults with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma at Chinese PLA General Hospital. It lists recruiting, but its October 15 start is still estimated, not actual first-infusion confirmation.

Approach/limitations: The bedside extracorporeal platform proposes automated collection, anti-CD19 CAR gene delivery, washing, quality checks and infusion on site. The protocol says infusion can occur within six hours if release criteria are met. This is not in-vivo CAR-T generation and does not establish that any patient has completed six-hour manufacture or that toxicity, access, durability or survival improves. Phase 1 evaluates dose-limiting toxicity and adverse events; Phase 2 evaluates response. No results are posted.

U.S. status / next: Investigational Chinese study; no U.S. approval established. Verify actual dosing and manufacturing/safety data; estimated primary completion October 30, 2028 and final completion October 30, 2029.

Sources: ClinicalTrials.gov · NCT07882641.

Development stage: RO7821657/NCT07883577 was first posted October 20. Roche plans an open-label, nonrandomized Phase 1 study with 405 estimated participants, beginning in microsatellite-stable colorectal cancer and expanding to non-squamous non-small-cell lung cancer. Status is not yet recruiting.

Evidence/limits: The official title describes a protease-activated T-cell-bispecific antibody targeting CEACAM5. This is an immune-cell engager, not an antibody-drug conjugate. The initial goals are adverse events, dose-limiting toxicity and dose selection; CRS and ICANS are specifically graded. Conditional activation is a design rationale, not proof of tumor restriction or avoidance of severe toxicity. No human response, progression-free survival or overall-survival results are posted.

U.S. status / next: Investigational. First-in-human registration is not FDA marketing approval or actual first dosing. October 26, 2026 is an estimated start; primary/final completion is estimated May 31, 2030. Recheck actual recruitment/dosing before advancing the stage description.

Sources: ClinicalTrials.gov · NCT07883577.

New disclosure, older study: Results for EO4010/NCT05589597 first posted October 19; actual follow-up ended May 30, 2025. The open-label, nonrandomized Phase 1/2 trial treated 25 patients with previously treated metastatic colorectal cancer in sequential cohorts using the microbiome-mimic peptide immunotherapy with nivolumab, with or without bevacizumab. It is terminated; the sponsor attributes stopping recruitment to development goals and explicitly says it was not a safety-driven decision. The exact stop-decision date is not supplied.

Results/harms: Immunogenicity at week 5 was recorded in 17/19 assessed participants; objective response in 1/25, with disease control in 6/25. These denominators and endpoints are distinct. The adverse-event table reports 6/25 with serious events over the 24-month reporting window; this is not evidence of zero harms or proof all were treatment-caused. There is no randomized comparator or reliable survival benefit estimate.

U.S. status / next: Investigational, without an approval established by this record. Immune activation does not establish tumor shrinkage, recurrence prevention or survival benefit. No announced new study or next results date is identified.

Sources: ClinicalTrials.gov · NCT05589597.

New disclosure, older trial: NCT03854032 first posted results October 19, while actual study completion was March 14, 2023. The sponsor states it terminated the neoadjuvant BMS-986205 (IDO1 inhibitor) plus nivolumab study in stage II–IV head-and-neck squamous-cell cancer because of toxicity concerns. The exact termination date and causal details are not established by the posting date.

Study/result: The flow table records 31 combination and 11 nivolumab-only participants plus 23 external/contemporaneous controls drawn from another study. The registry’s65 enrollment total must not be presented as 65 prospectively randomized patients. Five-week radiographic responses were 13/27 evaluable combination participants versus 4/11 nivolumab-only participants; these small descriptive results do not establish superior survival or cure. Serious adverse events were 6/31 versus 1/11, over the specified reporting period up to 14 months. The external cohort used different treatment/assessment arrangements and should remain separate.

U.S. status / next: This investigational combination is not made approved or standard care by the record. Several planned immune and patient-reported analyses were not performed. No further analysis date is promised.

Sources: ClinicalTrials.gov · NCT03854032.

Source and timing: Merck’s original release is dated October 22, 2026. The ESMO Presidential Symposium presentation is scheduled for October 24 and has not yet occurred as of this review. The release says the results were accepted for NEJM publication; an accessible published full paper was not verified.

Population and comparison: INTerpath-001 / NCT05933577 randomized 1,137 patients, 2:1, after complete resection of stage IIB–IV cutaneous melanoma. Intismeran autogene 1 mg every three weeks for up to nine doses plus pembrolizumab 400 mg every six weeks was compared with placebo plus pembrolizumab. Median follow-up was 24.6 months; the original release does not state the exact data-cutoff date.

Primary result: In the intention-to-treat population, recurrence-free survival was HR 0.58 (95% CI 0.45–0.75), two-sided p<0.001. Two-year RFS was 82.2% (79.3–84.8%) versus 70.0% (65.0–74.5%). The derived absolute difference is 12.2 percentage points. Distant-metastasis-free survival was HR 0.62 (0.45–0.85), p=0.002; two-year DMFS was 88.5% (86.0–90.6%) versus 80.2% (75.6–84.0%). Medians were not reached. Overall survival was immature: no mortality benefit or cure has been established.

Timing and estimand: The prespecified piecewise RFS HR was 0.99 (0.66–1.49) in the first six months and 0.42 (0.30–0.58) after six months. A modified population excluding participants who never received vaccine/placebo had HR 0.51 (0.39–0.67); this is a different analysis population and does not replace the primary ITT result.

Safety: Treatment-related adverse events occurred in 723/755 (95.8%) versus 342/380 (90.0%). Grade 3–5 treatment-related events were 107/755 (14.2%) versus 51/380 (13.4%). In the combination arm, common treatment-related events included pyrexia (52.2%), injection-site pain (51.0%) and fatigue (38.5%). Sponsor reporting of no new signal does not establish long-term safety.

Development/U.S. status: Intismeran remains investigational. Pembrolizumab approval does not approve this combination. This is recurrence prevention after cancer, not primary vaccination of healthy people. Full publication, regulatory filing and longer-term survival/safety follow-up remain to be verified.

Sources: merck.com · news release; ClinicalTrials.gov · NCT05933577.

Coverage and remaining gaps: Retrieved all saved named registries and all 79 discovery records. Appraised FDA approvals/labels, negative BNT113 topline results, BEX101 and RO7821657 protocols, the AZA-AEGEAN hold and older studies with newly posted tables. Root-supplied registry leads were included. CDX-1401 NCT03206047 stopped in 2020 for supply/product reasons and had zero vaccine-arm participants; it was excluded as vaccine failure. ESMO October 23–27 and INTerpath-001 October 24 remain future. The worldwide oncology, regulator, label and new-protocol inventory remains incomplete. Retain the full successful-check timestamp.

October 23 bounded delta: Verified the original Merck October 22 detailed INTerpath-001 release, including primary ITT estimates, harms and immature overall survival. The October 24 talk has not yet occurred. Checked ESMO sponsor schedules; unverified future talks, unpublished full tables and secondary NATALEE claims were not converted into results. This is a bounded delta, not exhaustive worldwide oncology monitoring.

Informal-source coverage: Original October 19 REGAL discussion continues to speculate about event 80, survival and an anniversary post without verified arm outcomes. The saved imminent-trigger claim remains unconfirmed rather than disproved. The sponsor index dynamically hid items; no official event-80 release was independently retrieved. CytoDyn/CLOVER investor ctDNA remarks remain an original-webcast access gap, not established efficacy. Full investor audio and ESMO abstract coverage remain incomplete. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Full coverage record.

U.S. status — October 8 approval: FDA approved IV Tecentriq (atezolizumab) with fluoropyrimidine- and oxaliplatin-based chemotherapy for adjuvant treatment of stage III mismatch repair–deficient colon cancer in adults and children aged 2 or older. Subcutaneous Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) received the same indication for patients aged 12 or older weighing at least 40 kg. This is postoperative cancer treatment, not primary prevention in healthy people. Approval alone does not establish payer coverage or local inventory.

Evidence: In ATOMIC (NCT02912559), 712 patients with completely resected stage III dMMR disease were randomized to atezolizumab plus mFOLFOX6 followed by atezolizumab, or mFOLFOX6 alone. FDA reports disease-free-survival HR 0.50 (95% CI 0.35–0.73); median DFS was not reached in either arm. The original March 25, 2026 paper reports 3-year DFS 86.3% (95% CI 81.8–89.8) versus 76.2% (70.9–80.6) and grade 3/4 adverse events in 84.1% versus 71.9%. These are previously published trial results supporting the new approval, not a new October efficacy analysis.

Limitations and harms: The FDA summary does not establish an overall-survival advantage. Immune-mediated adverse reactions and infusion reactions require monitoring; toxicity is material despite the recurrence benefit.

Next milestone: Longer-term survival and real-world access/safety follow-up; no dependable next release date identified.

Sources: FDA · regulatory information; NEJM · article.

Evidence — October 15 publication: NEONIPIGA (NCT04006262) enrolled 32 patients with localized dMMR/MSI-high gastric or gastroesophageal-junction adenocarcinoma. Treatment combined neoadjuvant nivolumab/ipilimumab, planned surgery and adjuvant nivolumab. At median follow-up of 48.3 months, 4-year overall survival was 84.1% (95% CI 65.8–93.0; all 32 patients); 4-year event-free survival was 83.5% (64.8–92.8; 31 surgery-eligible patients). Pathological complete response occurred in 17 of 29 surgical specimens, as previously reported.

Limitations and harms: This was not randomized. The authors explicitly found no clear survival improvement over other studies of surgery alone. Only 14 of 32 completed all planned treatment. Grade 3/4 treatment-related adverse events affected 6 patients during neoadjuvant therapy and 4 during adjuvant therapy; one death involved postoperative complications. No additional late toxic effects were reported. This cannot establish that surgery can safely be omitted.

Status and timing: This is a new journal report of long-term follow-up previously presented at ASCO 2026, not a fresh randomized readout or new U.S. approval. A randomized organ-preservation strategy needs further testing; no next result date was identified.

Sources: JAMA Network · article; ascopubs.org · article.

Remaining gaps: Focused cancer-treatment, recurrence and safety update. The missed October 8 FDA ATOMIC approval was checked against the regulator and the original March 25 paper; October 15 NEONIPIGA publication was appraised. Saved registries and 72 discovery records were retrieved; each record and the full worldwide oncology pipeline were not individually appraised. ESMO late-breaking abstracts and all ADC/cell/radiopharmaceutical entrants remain incomplete. Previously saved NRG-BR002, T-bren and LUTEON/ATLAS entries were deduplicated. No full successful-check advancement.

Informal-source coverage: Indexed original SELLAS October 5, 6, 11–15 discussions continue event-count modeling and imminent-readout speculation. The October 12 modeling thread predicts a December 24 announcement, while others predict earlier; these are incompatible anonymous estimates, not independent evidence. No official new REGAL final event/OS result was established in the checked sources; the saved imminent-event rumor remains unresolved. No repeated alert.

Full coverage record.

First posted: October 13, 2026. NCT07869836, SystImmune, registers a 520-person phase 3 comparison of trastuzumab brengitecan/T-bren/BL-M07D1, a HER2 ADC, against gemcitabine plus cisplatin or carboplatin in HER2-expressing metastatic urothelial cancer progressing after anti-PD-(L)1-based treatment.

The trial is randomized and open-label with masked outcome assessment. BICR progression-free survival in the primary population is primary; overall survival, intent-to-treat analyses, response and toxicity are secondary. Two investigational dose levels are listed.

Status/limits/U.S.: Recruiting, but September 2026 start remains estimated. No new response, PFS, OS or safety result is posted. HER2 expression and this treatment line must not be replaced with a tumor-agnostic claim. No U.S. marketing approval established by this record.

Next: December 2028 estimated primary and December 2029 final completion; neither is an announced public readout date.

Sources: ClinicalTrials.gov · NCT07869836.

First posted: October 13, 2026. LUTEON ATLAS/NCT07870746, Telix, plans 40 adults with CAIX-expressing advanced relapsed/recurrent clear-cell renal-cell carcinoma, following prior systemic therapy. Two regimens of 177Lu-TLX250/lutetium 177 girentuximab tetraxetan will be assessed to choose a later phase 3 dose.

The phase 2a design is open-label, nonrandomized and sequential, rather than a randomized standard-care comparison. Safety/tolerability dose optimization is primary; tumor/organ dosimetry, pharmacokinetics, response and survival monitoring are separate secondary measures. One secondary OS description refers to randomization despite the nonrandomized design; retain the inconsistency pending protocol clarification.

Status/limits/U.S.: Not yet recruiting, no efficacy/safety outcomes or new approval. This treats diagnosed kidney cancer; it is separate from kidney preservation and not evidence of longer survival.

Next: October 15, 2026 estimated start; December 31, 2028 primary and October 13, 2032 final completion estimates. Verify actual first treatment.

Sources: ClinicalTrials.gov · NCT07870746.

Remaining gaps: Read expanded oncology topic/state and September 5 overlap; retrieved 26 saved registries and 65 new-study matches. Appraised selected new phase 3 HER2 ADC and phase 2a CAIX radiopharmaceutical registrations; no duplicate NRG-BR002 or prior vaccine/regulatory events.; FDA oncology index retrieved but its latest visible update remains September; not a comprehensive Oct 13 approval/label audit. BNT122 registry active/not-recruiting versus August 28 sponsor termination/futility/OS imbalance remains a source conflict; no restart inferred. NRG-BR002 full paper/toxicity and global cellular/radiopharmaceutical census remain incomplete.

Informal-source coverage: REGAL event 80 imminent inference rechecked against sponsor news index and new Reddit discussions; no official trigger or topline confirmation retrieved, index lacks rendered dynamic entries. Leave unconfirmed without repeat alert. Leronlimab/AlphaDaRT investor forecasts not efficacy/approval evidence. All original investor calls/transcripts remain incomplete.

Full coverage record.

Source/event date: October 7, 2026 publication; this reports an older trial, not new October treatment. Evidence: Randomized NRG-BR002/NCT02364557, described in the investigator's release; full paper and toxicity tables remain unappraised.

The U.S./Canadian trial enrolled 129 patients, with 125 eligible for analysis, with at most four breast-cancer metastases. First-line systemic therapy alone was compared with systemic treatment plus ablation of all visible metastatic sites, usually SBRT. Median PFS was 23.0 versus 19.5 months; neither PFS nor overall survival improved significantly. The trial did not progress to phase 3.

Limits/safety: This does not establish equivalence, generalize to other cancers, or negate local treatment for pain or other symptoms. Low circulating-tumor-cell subgroup findings are exploratory, not a validated selection test. Detailed serious-toxicity counts were unavailable in the appraised primary release.

U.S. status / next milestone: No drug approval change. Biomarker-guided follow-up studies are described without a verified next readout date.

Investigator report; primary paper.

Source/event date: First posted October 6, 2026. Evidence: ImmProCure/NCT07860047, University Hospital Tübingen phase 2 registration.

The open-label randomized German study plans 84 men with biochemical prostate-cancer recurrence after treatment intended to cure, without distant metastases on PSMA-PET, selected for relatively slow progression. It compares VAC-XS15-PC01 multipeptide vaccine, CC-1 PSMA×CD3 bispecific antibody, and their combination. The primary endpoint is a PSA response of at least 50%; safety is monitored.

Limits: A PSA decrease or immune response is not proven metastasis prevention, survival benefit, or cure. No efficacy/safety results are posted. This treats recurrence after cancer, not prevention in healthy people.

Development / U.S. status: Registry lists recruiting, but the September 24 start remains an estimate. Tübingen is recruiting; the other listed German sites are not yet recruiting. Both experimental approaches remain investigational, without a new U.S. approval.

Next milestone: March 31, 2029 primary and March 31, 2030 final completion, registry estimates rather than readout promises.

Original registry.

Source/event date: First posted October 6, 2026. Evidence: VA-sponsored phase 2 NCT07859592.

The study plans 30 participants with advanced/metastatic or recurrent lung adenocarcinoma after at least one checkpoint-inhibitor line. LabVax 3(22)-23, targeting the labyrinthin antigen, is combined with GM-CSF and pembrolizumab. It uses an open-label sequential design without a standard-treatment control arm. Objective response is primary; PFS, OS and toxicity are also tracked.

Limits/safety: No results establish response, survival or safety. An antigen-directed immune response would not itself establish clinical benefit. The protocol can stop for insufficient safety or response. This is treatment of existing advanced cancer, distinct from recurrence prevention after surgery or primary prevention.

Development / U.S. status: Not yet recruiting. December 1, 2026 start is estimated; experimental vaccine access is through research, not an approval.

Next milestone: November 30, 2030 primary and December 1, 2035 final completion estimates; neither is a guaranteed publication date.

Original registry.

Source dates: ACE723 first posted October 6; REGN13089-M404-M2980 October 7, 2026. Evidence: New formal human trial registrations.

ACE723 — Acepodia, NCT07861425: A GPC3-targeted dual-payload ADC, phase 1, 70 planned participants with unresectable/metastatic hepatocellular carcinoma after checkpoint-inhibitor-containing treatment. Dose-limiting toxicity, tolerability and dose selection are primary. Registry says not yet recruiting, with November 2026 start and May 2030 completion estimates.

REGN13089-M404-M2980 — Regeneron, NCT07863024: MET-targeting ADC, phase 1/2, 320 planned adults with previously treated advanced solid tumors. Dose escalation focuses on safety; expansion includes objective response and is listed as randomized. The record does not describe a standard-therapy comparator or the exact allocation. Not yet recruiting; November 23, 2026 start and March 10, 2031 completion are estimates.

Limits / U.S. status: Neither has posted efficacy/safety outcomes or a new marketing approval. Target binding, dual payloads and response endpoints cannot establish superior survival.

ACE723 registry; MET ADC registry.

Remaining gaps: Read broad oncology topic/state, September5 overlap, registry collection and Oct2–9 new-study discovery. No duplicate evERA, IMpassion050, daraxonrasib, belzutifan/lenvatinib or prior vaccine schedule events.; Appraised Oct7 MDAnderson NRG-BR002 investigator report; journal full paper and primary PubMed page inaccessible. Detailed hazard ratios from secondary abstract mirrors are deliberately omitted pending primary access.; BNT122-01 source conflict: Aug28 BioNTech discontinuation/futility/OS-imbalance statement versus Oct7 NCT04486378 active-not-recruiting record with November2026 estimate. Do not infer resumed treatment from registry. Broad cellular/radiopharmaceutical and global oncology census remains incomplete; all treatment-line safety labels not refreshed.

Informal-source coverage: Revisited October2 REGAL any-day event80 speculation and official August11 sponsor release. No new official confirmation of event80 or topline result found in focused searches; retain unconfirmed and do not re-alert. Event accrual cannot identify randomized-arm survival or predict approval. Full investor-call/audio sweep remains incomplete.

Full coverage record.

Source/event date: September 24, 2026 publication; data cutoff August 24, 2023. Evidence: Peer-reviewed final follow-up, IMpassion050/NCT03726879; primary abstract appraised.

The randomized phase 3 trial enrolled 454 patients with high-risk HER2-positive early breast cancer. Atezolizumab or placebo was added to neoadjuvant pertuzumab/trastuzumab/chemotherapy and continued after surgery with HER2 therapy. Median follow-up was 44.2 / 43.4 months. Three-year EFS 91.4% versus 89.0%; HR 0.90 (95% CI 0.50–1.59). Among 434 surgical/postneoadjuvant participants, DFS 92.9% versus 88.5%; HR 0.71 (0.38–1.32). Neither difference was statistically significant; numerical subgroup findings do not reverse the earlier null pathologic-complete-response result or establish survival benefit.

Safety: Adjuvant special-interest AEs were 59.4% versus 47.0%, with none grade 5 in that subset. This is not a statement that the whole trial had no fatal events; the full safety appendix remains unappraised.

U.S. status / next milestone: No new approval from publication; this regimen should not be generalized to other breast-cancer subtypes or cancer prevention. No announced next confirmatory/readout date.

Primary abstract; full paper DOI.

Source/event date: 2026-09-30. Evidence: Peer-reviewed primary abstract and sponsor publication announcement.

Phase 3 open-label evERA (NCT05306340; 373 patients) compared giredestrant plus everolimus against physician-selected endocrine therapy plus everolimus after CDK4/6-inhibitor/endocrine treatment in ER-positive/HER2-negative advanced breast cancer. Median progression-free survival was 8.8 versus 5.5 months overall (HR 0.56, 95% CI 0.44–0.71), and 10.0 versus 5.5 among 207 patients with ESR1 mutations (HR 0.38, 0.27–0.54). Overall survival remains immature; longer survival is not established. Any adverse events occurred in 98.9% versus 96.8%; stomatitis 47.3% versus 48.9%, diarrhea 26.9% versus 22.6%, anemia 23.6% versus 21.0%. Severe-event/discontinuation tables remain unappraised. This is a new publication of an existing trial, not a new trial or topline. Giredestrant remains investigational. Sponsor reports a December 18 FDA target for ESR1-mutated advanced disease; the separate adjuvant application concerns a different population. Primary paper.

Next milestone: December 18, 2026 — sponsor-reported FDA action target for the advanced ESR1-mutated breast-cancer application; not guaranteed approval.

Primary paper; gene.com · news release; ClinicalTrials.gov · NCT05306340.

Source date: 2026-09-28. Evidence: Randomized phase 2 conference abstract and investigator-society report.

SOFT Preop enrolled 102 people with operable or selected locally advanced pancreatic cancer after chemotherapy; four withdrew. Five SBRT sessions were compared with 28 radiation sessions plus concurrent chemotherapy. Among 83 surgical completers, node positivity was 41% versus 38% (p=.754), missing the hypothesized advantage of longer chemoradiation. Physical function and fatigue were better preserved during radiotherapy, with no significant quality-of-life difference after surgery. Median survival from enrollment after initial chemotherapy was 26.04 months (95% CI 17.9–59.28) versus 42.96 (18.72–54.72), p=.639; median follow-up was 3.4 years.

Limitations: This small superiority trial does not establish survival equivalence or noninferiority. Quality-of-life effect sizes and confidence intervals were absent from the available abstract. SBRT included regional nodes; results cannot be generalized to every SBRT regimen. Exact registry ID not verified.

Safety: No significant surgical-complication difference reported; full toxicity counts were not provided.

U.S. status: A technique-comparison study, not a new drug authorization or recommendation for every pancreatic cancer patient.

Next milestone: The abstract is public. The program scheduled the scientific talk September 29 at 14:55 Eastern, after a scheduled September 28 press briefing; actual delivery was not verified. Larger studies remain undated.

ASTRO investigator announcement; ASTRO LBA08 abstract and session.

Source date: 2026-09-28. Evidence: Sponsor trial-development announcement.

Biohaven reports enrollment has begun for its FGFR3 antibody–drug conjugate BHV-1530 plus cemiplimab in advanced solid tumors. NCT06874335 is an open-label phase 1 dose study. Its July 9 registry update lists 140 planned participants across the program, not 140 in this new cohort; no results are posted. The study began March 20, 2025.

Limitations: The release does not provide new cohort-specific response rates, denominators or comparative survival. Previously disclosed partial responses cannot establish superiority.

Safety: Sponsor reports no dose-limiting or typical FGFR-inhibitor toxicities in previously disclosed data; small early exposure and missing detailed tables preclude broad safety conclusions.

U.S. status: BHV-1530 remains investigational; cemiplimab approval in other settings does not approve this combination.

Next milestone: Updated phase 1 presentation scheduled November 19, 2026 at 10:00 in Barcelona (release does not explicitly label the time zone). Registry completion March 2029 is an estimate.

Biohaven September 28 release; Original registry.

Source date: 2026-08-26. Evidence: Recovered FDA approval; historical baseline, not new September news. Baseline addition; not new news.

FDA approved Rasonque (daraxonrasib) August 26 for metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent therapy is unsuitable. RASolute 302 (NCT06625320) randomized 500 previously treated patients. Median overall survival was 13.2 versus 6.7 months with chemotherapy; HR 0.40 (95% CI 0.30–0.53). Median PFS was 7.2 versus 3.6 months; HR 0.49 (0.38–0.64).

Limitations: This is evidence for a defined advanced-cancer setting, not cancer prevention, cure or an individual prediction. A September 28 hospital story repeats the August approval.

Safety: Warnings include skin/soft-tissue toxicity, oral inflammation, diarrhea, GI perforation, lung inflammation and embryo-fetal harm.

U.S. status: FDA-approved August 26, 2026 for the specified population; individual access/coverage not checked.

Next milestone: Longer follow-up and trials in other settings; no next exact date verified.

FDA original approval.

Source date: 2026-09-24. Event date: 2026-09-24. Evidence: FDA approval and randomized phase 3 evidence.

Welireg plus Lenvima is approved for advanced renal-cell carcinoma with a clear-cell component after PD-1/PD-L1 therapy. LITESPARK-011 (NCT04586231; n=747) compared the combination with cabozantinib. Median PFS: 14.6 versus 10.6 months; HR 0.74 (95% CI 0.61–0.89). Response: 53% versus 40%.

Limitations: Final overall survival was not statistically significant: 33.7 versus 28.6 months, HR 0.85 (0.70–1.03). Better PFS does not establish longer survival; this is cancer treatment, not kidney preservation.

Safety: Belzutifan carries embryo-fetal, anemia and hypoxia risks. Lenvatinib adds hypertension, cardiac, renal/hepatic and hemorrhage risks.

U.S. status: FDA-approved September 24, 2026 for this combination and population; local stock and coverage not checked.

Next milestone: Longer clinical and real-world follow-up; no verified next public date.

FDA belzutifan–lenvatinib approval.

Source date: 2026-09-23. Event date: 2026-09-23. Evidence: FDA approval with single-arm evidence.

Lyrfigtu is approved for previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. REFOCUS (NCT04526106) included 116 FGFR-inhibitor-naive patients previously treated with chemotherapy with or without immunotherapy. Response was 46% (95% CI 36–55); median response duration 11.8 months (7.5–13.0).

Limitations: Open-label single-arm evidence cannot establish comparative survival benefit. Keep this molecularly selected cancer population distinct from unselected bile-duct cancer.

Safety: Ocular toxicity, hyperphosphatemia with soft-tissue mineralization, and embryo-fetal toxicity are key warnings.

U.S. status: FDA-approved September 23, 2026 for the specified indication; availability and coverage not checked.

Next milestone: Comparative and longer-term outcomes remain undated.

FDA lirafugratinib approval.

Source date: 2026-09-18. Event date: 2026-09-18. Evidence: FDA approval and randomized trial subgroup.

Inluriyo plus Verzenio is approved after endocrine therapy for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. EMBER-3 (NCT04975308) enrolled 874 overall. The exploratory ESR1-mutant combination-versus-imlunestrant subgroup included 159: median PFS 11.1 versus 5.5 months; HR 0.53 (95% CI 0.35–0.80). Guardant360 CDx is an approved companion test.

Limitations: Overall survival remained immature (35% deaths). The approved combination population is narrower than the whole study. September 18 approval recovered during this overlap search.

Safety: Diarrhea, neutropenia, interstitial lung disease/pneumonitis, liver injury, thromboembolism and embryo-fetal harm remain relevant.

U.S. status: FDA-approved September 18, 2026 for this mutation-defined combination indication.

Next milestone: Mature survival and further follow-up; no announced exact date verified.

FDA imlunestrant combination approval.

Source date: 2026-09-24. Event date: 2026-09-24. Evidence: Sponsor human-trial initiation.

Astellas reports first dosing in its phase 3 trial of the KRAS G12D protein degrader versus docetaxel. NCT07566052 plans approximately 356 patients with unresectable or metastatic KRAS G12D NSCLC progressing after platinum chemotherapy and checkpoint inhibition. Randomized open-label study; co-primary endpoints are centrally assessed PFS and overall survival.

Limitations: First dosing is an operational milestone, not comparative efficacy. Its separate first-line pancreatic-cancer phase 3 began in April.

Safety: Phase 3 comparative safety remains pending.

U.S. status: Investigational, not approved for the proposed uses.

Next milestone: Pancreatic translational analyses scheduled September 27 poster and September 28 short talk at AACR; distinct from lung-cancer phase 3 results. No phase 3 readout date verified.

Astellas first-dosing release.

Source date: 2026-09-23. Event date: 2026-09-23. Evidence: Peer-reviewed uncontrolled phase 1 study.

Among 38 infused patients with heavily pretreated relapsed/refractory myeloma, all responded; 30/38 had complete responses. NCT04155749 enrolled 40. Median follow-up was 38.1 months; median PFS 30.2 months (95% CI 16.6–36.2), 24-month PFS 57% (39–71), and 36-month survival 65% (46–79).

Limitations: Small uncontrolled dose study; neither complete response nor survival estimates establish cure or superiority to another CAR-T. Laboratory binder comparisons are not a clinical head-to-head trial.

Safety: All 38 had adverse events and 37/38 grade ≥3 events. At the recommended dose, 94% had grade 1/2 cytokine-release syndrome; none grade ≥3. ICANS included one grade 3 event. No delayed/non-ICANS neurotoxicity observed does not exclude rare risks.

U.S. status: Investigational; this paper is not an approval.

Next milestone: Larger confirmatory data and regulatory follow-up; no new date established by this publication.

NEJM anito-cel primary publication.

Source date: 2026-09-23. Event date: 2026-09-23. Evidence: Peer-reviewed observational human study.

Nature Medicine described persistent gut inflammation after BCMA CAR-T therapy, informing safety monitoring as cellular therapies expand. Researchers studied ten patients with enterocolitis after ciltacabtagene autoleucel, seven CAR-T-treated controls without enterocolitis and 26 healthy volunteers. Tissue analyses linked mucosal CAR-T persistence and inflammatory remodeling. Two patients improved clinically, endoscopically and histologically after upadacitinib.

Limitations: These were multiple-myeloma patients receiving BCMA CAR-T, not autoimmune patients receiving CD19 CAR-T. Selected observational cases cannot estimate incidence or establish a class-wide causal mechanism. Two uncontrolled rescue treatments do not establish an effective standard treatment.

Safety: The serious gut complication is the study focus; this is mechanistic evidence about an already recognized risk.

U.S. status: No autoimmune CAR-T approval or approval of upadacitinib for this complication is established by this study.

Next milestone: Controlled management studies and longer follow-up; timing unknown.

Persistence of mucosal CAR-T cells and inflammatory remodeling.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: Sponsor conference announcement.

Moderna identifies ESMO LBA1 as the detailed phase 3 presentation for intismeran plus pembrolizumab in resected stage IIB–IV melanoma. The Presidential Symposium is scheduled for October 24 at 16:30 CEST (10:30 Eastern). The August positive RFS/DMFS topline is already recorded; this announcement adds timing, not new numerical efficacy.

Limitations: Adjuvant recurrence prevention after melanoma treatment, not cancer prevention in healthy people. Numerical benefit, adverse events and survival maturity must be appraised when disclosed.

Safety: No new safety table in the scheduling release.

U.S. status: Investigational combination.

Next milestone: October 24, 2026: scheduled ESMO LBA1; sponsor investor webcast follows at 19:00 CEST.

Moderna September 21 announcement.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: Sponsor preliminary phase 1/2 report.

Three anti-AAV-antibody-negative patients with relapsed/refractory ALL achieved MRD-negative complete responses after VNX-101; the broader SENTRY-CD19 study has dosed nine patients with several CD19-positive malignancies. NCT06533579 is an uncontrolled phase 1/2 dose-escalation study. VNX-101 uses in-vivo gene delivery to produce a CD19/CD3 T-cell engager. The first responding patient remained MRD-negative through day 260 and then received a stem-cell transplant.

Limitations: The three-patient selected ALL subgroup is not the entire nine-patient response denominator. No comparative survival or cure evidence; later transplant complicates durability attribution.

Safety: Cytokine-release syndrome and ICANS occurred during dose escalation and reportedly resolved with standard care. The release omits grades and event denominators.

U.S. status: Investigational; FDA designations are not approval.

Next milestone: Further dose optimization and follow-up are undated; registry estimates primary completion June 2027, not a promised publication date.

Vironexis September 21 release; SENTRY-CD19 registry.

Source date: 2026-09-16. Evidence: Sponsor topline; randomized phase 3.

CELESTIMO reports improved progression-free survival with mosunetuzumab plus lenalidomide in previously treated follicular lymphoma; overall survival is immature. NCT04712097 compares mosunetuzumab plus lenalidomide with rituximab plus lenalidomide after at least one prior treatment. The registry lists 478 actual participants. Genentech reports that the interim primary endpoint was met, without releasing a hazard ratio or absolute PFS estimates.

Limitations: PFS benefit must not be called a demonstrated survival benefit. The study supports a potential earlier-line indication and confirmatory regulatory review; neither action is completed by the topline announcement.

Safety: Sponsor reports no new safety signal, but comparative adverse-event tables are pending. Known mosunetuzumab risks include serious cytokine-release syndrome and infections.

U.S. status: Existing third-line-or-later monotherapy approval is separate from the investigational second-line combination.

Next milestone: Full results at an unnamed upcoming medical meeting and regulatory submissions; no firm date.

Genentech, September 16; CELESTIMO registry.

Source date: 2026-09-17. Evidence: Sponsor development milestone.

The phase 3 SGT-610 study has completed its final patient visit; the sponsor forecasts topline results in late November 2026. SGT-610-01 tests topical patidegib 2% versus vehicle for 12 months to prevent new facial basal-cell carcinomas in adults with Gorlin syndrome. It enrolled 113 people; 102 completed. Database lock and analysis are next, with assignments still blinded.

Limitations: No efficacy or comparative safety result is released. This inherited high-risk cancer-prevention setting does not establish cosmetic benefit or prevention in the general population.

Safety: The completed-visit announcement contains no new outcome-level safety analysis.

U.S. status: Investigational; trial completion and designations are not approval.

Next milestone: Late November 2026 topline: sponsor forecast, not a scheduled day.

Sol-Gel, September 17.

Related findings:

• Ketamir-2 prepares a controlled neuropathy trial: MIRA submitted a phase 2a chemotherapy-induced neuropathy protocol for ethics review; site initiation is targeted for Q1 2027, not confirmed underway.

Current position: this is a credible category with a recent phase 3 success, but results depend on the cancer, treatment setting and combination. A vaccine intended to prevent recurrence is still treatment for people who have already had cancer. It is not evidence that healthy people can receive a general cancer-prevention vaccine. Established HPV and hepatitis B vaccination prevent infection-related cancers; the experimental tumor-antigen approaches below are a different research question. FDA-approved sipuleucel-T already provides a treatment-vaccine precedent for selected metastatic prostate cancer patients. NCI treatment-vaccine overview; ACS vaccine distinctions.

Intismeran autogene, formerly V940/mRNA-4157 — Merck/Moderna. On August 19, 2026, the sponsors reported that phase 3 INTerpath-001 (NCT05933577) met recurrence-free survival and distant-metastasis-free survival endpoints in completely resected stage IIB–IV melanoma. The trial enrolled 1,137 patients and randomized them 2:1 to individualized mRNA therapy plus pembrolizumab or the pembrolizumab control regimen. The release reports no new safety signals, but does not provide the phase 3 hazard ratios, absolute event rates or mature overall-survival results. This is a sponsor topline announcement, not yet a fully appraised phase 3 paper. Do not substitute earlier phase 2 effect sizes for these results. Full data are promised at an upcoming international meeting, with no named meeting or date in this release; regulatory engagement is planned, not an approval. August 19 announcement.

The platform also has trials in other cancers, including phase 3 adjuvant non-small-cell lung cancer INTerpath-002 (NCT06077760). An August 2026 investigator/sponsor publication describes the clinical portfolio and production pathway. Manufacturing a unique product from each patient's tumor creates questions about turnaround, unsuccessful manufacture and treatment access; melanoma efficacy cannot be assumed in lung, kidney or bladder cancer. Clinical development and manufacturing paper.

Autogene cevumeran, BNT122/RO7198457 — BioNTech/Genentech. The August 28, 2026 update is a significant negative result: the sponsors terminated phase 2 BNT122-01 (NCT04486378), which tested vaccine monotherapy against watchful waiting after surgery in ctDNA-positive, high-risk stage II/stage III colorectal cancer. A futility boundary had been crossed in October 2025. The later review found an overall-survival numerical imbalance and little prospect that continued follow-up would change efficacy conclusions. The DSMB recommended stopping treatment and the trial; the sponsor separately states that no new safety signal was identified. The public release supplies neither the numerical survival results nor enough detail to resolve the imbalance. Retain both statements and await full reporting. The pancreatic combination study was explicitly unaffected. August 28 sponsor statement.

Pancreatic cancer, IMcode003 (NCT05968326). This randomized phase 2 trial compares autogene cevumeran plus atezolizumab and mFOLFIRINOX with mFOLFIRINOX alone after resection. It is a more informative test than comparing immune responders with nonresponders in a small uncontrolled early study: responder status itself can reflect prognosis. The sponsor's August statement confirms continuation. No reliable next public readout date was verified. Sponsor trial description.

Prevention/interception: Nous-209 in Lynch syndrome (NCT05078866). A January 16, 2026 peer-reviewed phase 1b/2 report describes 45 participants without active cancer. This shared frameshift-antigen vaccine produced responses in all 37 immunologically evaluable participants; 85% retained detectable responses at one year. There were no intervention-related serious adverse events. The initial cohort was single-arm, and safety/immunogenicity were coprimary endpoints: these results do not yet show fewer cancers or improved survival. This is prevention research in a hereditary-risk population, not a general-population indication. Follow revaccination, lesion/cancer incidence and controlled trials. Nature Medicine paper; NCI trial.